R9Z.F ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Market cap
- EUR 131M
- P/E
- -
- P/B
- 1.44x
- ROE
- -27.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is R9Z.F undervalued?
Graham numberThe Graham number of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. fundamental analysis
No fundamental analysis for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. yet.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic sy…
Full company profileImmuneOnco Biopharmaceuticals (Shanghai) Inc. financial statements
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.07M | 538K | 386K | 74.1M | 154M |
| Gross Profit | - | - | - | 74.1M | 153M |
| Operating Income | -215M | -382M | -391M | -308M | -213M |
| EBITDA | - | -384M | -355M | -292M | -199M |
| Net Income | -733M | -403M | -379M | -316M | -219M |
| EPS | -1.96 | -1.08 | -1.01 | -0.78 | -0.51 |
| Balance Sheet | |||||
| Total Assets | 893M | 840M | 875M | 922M | 1.10B |
| Total Liabilities | 2.49B | 60.8M | 126M | 244M | 308M |
| Shareholders' Equity | -1.60B | 779M | 748M | 679M | 791M |
| Cash & Short-term Investments | 668M | 635M | 307M | 478M | 680M |
| Cash Flow | |||||
| Operating Cash Flow | -191M | -239M | -368M | -128M | -203M |
| Capital Expenditure | 125M | 23.2M | 2.69M | 10.4M | 1.31M |
| Free Cash Flow | -316M | -262M | -370M | -138M | -204M |
| Ratios | |||||
| ROE | - | -51.7% | -50.7% | -46.5% | -27.6% |
| ROA | -82.1% | -48.0% | -43.4% | -34.3% | -19.9% |
| Net Profit Margin | -14,465.1% | -74,887.4% | -98,305.4% | -426.0% | -141.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. dividends
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has not paid dividends in the last 5 fiscal years.
Who owns ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Insiders 33.87%
- Institutions 0.47%
- Public & others 65.66%
- Shares outstanding 418M
- Free float 277M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. company profile
- Company name
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Ticker
- R9Z.F
- ISIN
- CNE100006624
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 197
- Fiscal year end
- December
- Address
- Unit 15, Shanghai, China
- Phone
- 86 21 3801 6387
- Website
- immuneonco.com
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase Ib/II clinical trial to treat solid tumors; and IMM2520, which is in Phase I clinical trial for solid tumors. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. management
9- Dr. Wenzhi TianFounder, CEO, Chief Scientific Officer & Chairman of the Board · born 1965
- Mr. Song LiVP of Research & Development and Executive Director · born 1986
- Mr. Ruliang ZhangDeputy GM, Senior VP & Executive Director · born 1985
- Ms. Mei GuanJoint Company Secretary, VP of the Financing & Investment Strategy Department and Executive Director · born 1983
- Dr. Xiaodong GanCounsel · born 1964
- Dr. Zikai Xiong Ph.D.Senior Vice President · born 1981
- Dr. Weihai HeChief Business Officer · born 1973
- Dr. Zhuli WuChief Medical Officer · born 1984
- Mr. Kin Wai LiJoint Company Secretary · born 1989